BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26829600)

  • 21. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
    Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.
    McCune JS; Baker KS; Blough DK; Gamis A; Bemer MJ; Kelton-Rehkopf MC; Winter L; Barrett JS
    J Clin Pharmacol; 2013 Mar; 53(3):264-75. PubMed ID: 23444282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen.
    Huang J; Li Z; Liang W; Chen B; Hu J; Yang W
    J Clin Pharmacol; 2019 May; 59(5):638-645. PubMed ID: 30512187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
    Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
    J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective appraisal of busulfan dose adjustment in children.
    Dupuis LL; Najdova M; Saunders EF
    Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.
    Sandström M; Karlsson MO; Ljungman P; Hassan Z; Jonsson EN; Nilsson C; Ringden O; Oberg G; Bekassy A; Hassan M
    Bone Marrow Transplant; 2001 Oct; 28(7):657-64. PubMed ID: 11704788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
    Neroutsos E; Athanasiadou I; Paisiou A; Zisaki K; Goussetis E; Archontaki H; Tsirigotis P; Kitra M; Grafakos S; Spyridonidis A; Dokoumetzidis A; Valsami G
    J Pharm Pharmacol; 2021 Sep; 73(10):1340-1350. PubMed ID: 34244783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults.
    Diestelhorst C; Boos J; McCune JS; Russell J; Kangarloo SB; Hempel G
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):991-1000. PubMed ID: 24061863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
    Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
    Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosing algorithm revisit for busulfan following IV infusion.
    Wang Y; Kato K; Le Gallo C; Armstrong E; Rock E; Wang X
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):505-12. PubMed ID: 25561350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
    van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
    Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation.
    Takamatsu Y; Sasaki N; Ogata K; Yukawa E; Jimi S; Hara S; Tamura K
    Cancer Chemother Pharmacol; 2010 May; 65(6):1203-7. PubMed ID: 20169347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L; Leger F; Lennon S; Puozzo C
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic monitoring of busulfan in pediatric bone marrow transplantation.
    Krivoy N; Hoffer E; Tabak A; Elhasid R; Arush MW; Stein J; Yaniv I; Rowe JM
    Pediatr Hematol Oncol; 2002; 19(1):31-7. PubMed ID: 11833485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.
    Danielak D; Twardosz J; Kasprzyk A; Wachowiak J; Kałwak K; Główka F
    Eur J Clin Pharmacol; 2018 Jan; 74(1):79-89. PubMed ID: 28975382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
    Long-Boyle JR; Savic R; Yan S; Bartelink I; Musick L; French D; Law J; Horn B; Cowan MJ; Dvorak CC
    Ther Drug Monit; 2015 Apr; 37(2):236-45. PubMed ID: 25162216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate.
    Sjöö F; El-Serafi I; Enestig J; Mattsson J; Liwing J; Hassan M
    Clin Drug Investig; 2014 Jan; 34(1):43-52. PubMed ID: 24178237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of oral busulfan in children.
    Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
    Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
    Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.